ADAR1 Capital Management LLC has increased its stake in Inhibikase Therapeutics, Inc. by 0.4%, bringing its total holdings to over five million shares. The institutional investor’s move indicates growing confidence in the biotech firm, which now comprises about 2.1% of ADAR1’s portfolio.

ADAR1 Capital Management has significantly raised its stake in Contineum Therapeutics, increasing its shareholding by 105.2% in the first quarter. The purchase brings its total shares in the biotech company to 168,765, valued at approximately $1.18 million.